Potassium channel inhibitors and method
AssigneeBristol-Myers Squibb Company
InventorsJohn Lloyd, Heather J. Finlay, Wayne Vaccaro, Karnail S. Atwal, Michael F. Gross, Kerry L. Spear
Life of this patent
Estimating the term…
Abstract
Indanes, benzopyrans and analogues thereof are potassium channel inhibitors and blockers of IKur and have the structure where A, B, D, Q, X1, R, R1, X2 and R2 are as defined herein. These compounds are useful as antiarrhythmic agents. In addition, a method is provided for preventing cardiac arrhythmia employing the above compounds.
Claims11
A compound having the structure
- or pharmaceutically acceptable salts thereof, prodrug esters thereof, or all stereoisomers thereof, wherein
- A and B are CH and D is N;
- X1 is
- wherein the heteroatom is linked to the aromatic ring;
- (where R3 and R4 are independently H, alkyl, arylalkyl or cycloalkyl, or R3 and R4 can be taken together with the carbon to which they are attached to form a 5 to 8 carbon containing ring);
- R is H, alkyl, alkenyl, aryl, arylalkyl, heterocycloalkyl, cycloalkyl, or cycloalkylalkyl;
- R1 is arylalkyl, aryl, alkenyl, heteroaryl, heteroarylalkyl,
- (where R5a is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl), or
- (where R6 and R7 are independently selected from aryl, arylalkyl or cycloalkyl;
- X2 is a single bond,
- or —O— (where R8 is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl);
- R2 is H, alkyl, arylalkyl,
- (where R10 and R11 are independently selected from H, alkyl, arylalkyl or cycloalkyl, or R10 and R11 can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring);
- and
- (where R12 is alkyl, arylalkyl, aryl,
- heterocycle, heterocycloalkyl,
- (where R14 can be any of the R8 groups), alkoxy, CF3, aryloxy, arylalkoxy, cycloalkyl or cycloalkylalkyl, and where R15 and R16 are independently selected from H, alkyl, arylalkyl, aryl, heterocyclo, cycloalkyl, amino, aminoalkyl, or heterocycloalkyl, or R15 and R16 can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring which may optionally contain an additional nitrogen atom in the ring and/or an amino group or an aminoalkyl group attached to the ring);
- and
- R13 is
- (wherein this moiety is as defined with respect to R12).
A compound having the structure
- where R is H
- R1 is phenyl or phenyl substituted with alkyl or halogen;
- X2 is O;
- R2 is H;
- R3 is alkyl;
- R4 s alkyl;
- and Q is
- where
- where R15 and R16 are independently selected from H, alkyl, arylalkyl, aryl, heterocyclo, cycloalkyl, amino, aminoalkyl or heterocycloalkyl or R15 and R16 can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring which may optionally contain an additional nitrogen atom in the ring and/or an amino group or an aminoalkyl group attached to the ring.
A method for preventing or treating cardiac arrhythmia or atrial arrhythmia, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound which has the structure
- or pharmaceutically acceptable salts thereof, prodrug esters thereof, or all stereoisomers thereof, wherein
- A and B are CH and D is N;
- wherein the heteroatom is linked to the aromatic ring;
- (where R3 and R4 are independently H, alkyl, arylalkyl or cycloalkyl, or R3 and R4 can be taken together with the carbon to which they are attached to form a 5 to 8 carbon containing ring);
- R is H, alkyl, alkenyl, aryl, arylalkyl, heterocycloalkyl, cycloalkyl, or cycloalkylalkyl;
- R1 is arylalkyl, aryl, alkenyl, heteroaryl, heteroarylalkyl,
- (where R5a is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl), or
- (where R6 and R7 are independently selected from aryl, arylalkyl or cycloalkyl;
- X2 is a bond,
- or —O— (where R8 is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl);
- R2 is H, alkyl arylalkyl,
- (where R10 and R11 are independently selected from H, alkyl, arylalkyl or cycloalkyl, or R10 and R11 can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring);
- and
- (where R12 is alkyl, arylalkyl, aryl
- heterocycle, heterocycloalkyl
- (where R14 can be any of the R8 groups), CF3, alkoxy, aryloxy, arylalkoxy, cycloalkyl or cycloalkylalkyl, and where R15 and R16 are independently selected from H, alkyl, arylalkyl, aryl, heterocyclo, amino, aminoalkyl, cycloalkyl or heterocycloalkyl, or R15 and R16 can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring which may optionally contain an additional nitrogen atom in the ring and/or an amino group or an aminoalkyl group attached to the ring);
- and
- R13 is
- (wherein this moiety is as defined with respect to R12).
Dependencies are inferred from the claim text.